PTM-001-ADC stains both the primary colon adenocarcinoma and the matched lymph node metastasis of the primary tumor (summarized in the images to the right and table below)
This staining pattern strongly suggests that PMT-001-ADC could therapeutically affect both the primary colon cancer site as well as the metastatic satellites of the primary colon cancer.
As many colon cancer discoveries occur after “escape” or after the development of metastatic satellites, PTM-001-ADC offers an all encompassing solution to the treatment of both the primary tumor source and the escaped metastatic satellite tumors.
Actively seeking partners with expertise in Linker-Toxin optimization and discovery for collaboration or co-development
PTM-001-ADC: selectively targets Colon Cancer Tissue but not normal Colon Tissue
(Left/Mobile Top) in sit image, colon mass through a colonoscope. (Right/Mobile Bottom) PTM-001 or Human IgG staining on Tissue Microarray composed of colon adenocarcinoma and normal (tumor adjacent) tissue.
PTM-001-ADC Proof Of Concept:
PTM-001-ADC (SMCC-DM1 at DAR = 1.6) demonstrates strong cytotoxicity against the colon cancer cell lines Colo-205 at 16 and 4nM over 3 days. AGS cells (Gastric Cancer) does not support PTM-001 binding and is not affected by PTM-001-ADC at 16nM
Colo205 Cells, PTM-001-DM1 (16nM)
Colo205, PTM-001-DM1 (4nM)
Colo205 Cells
AGS Cells, PTM-001-DM1 (16nM)